Treatment of Aspergillosis.

Loading...
Thumbnail Image

Date

2018-08

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

4
views
14
downloads

Citation Stats

Abstract

Infections caused by Aspergillus spp. remain associated with high morbidity and mortality. While mold-active antifungal prophylaxis has led to a decrease of occurrence of invasive aspergillosis (IA) in those patients most at risk for infection, breakthrough IA does occur and remains difficult to diagnose due to low sensitivities of mycological tests for IA. IA is also increasingly observed in other non-neutropenic patient groups, where clinical presentation is atypical and diagnosis remains challenging. Early and targeted systemic antifungal treatment remains the most important predictive factor for a successful outcome in immunocompromised individuals. Recent guidelines recommend voriconazole and/or isavuconazole for the primary treatment of IA, with liposomal amphotericin B being the first alternative, and posaconazole, as well as echinocandins, primarily recommended for salvage treatment. Few studies have evaluated treatment options for chronic pulmonary aspergillosis (CPA), where long-term oral itraconazole or voriconazole remain the treatment of choice.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.3390/jof4030098

Publication Info

Jenks, Jeffrey D, and Martin Hoenigl (2018). Treatment of Aspergillosis. Journal of fungi (Basel, Switzerland), 4(3). p. E98. 10.3390/jof4030098 Retrieved from https://hdl.handle.net/10161/28629.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Jenks

Jeffrey Daniel Jenks

Adjunct Associate Professor in the Department of Medicine

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.